Skip to main content
Funded Studies

Tanya Z. Fischer, MD, PhD

Vice President, CNS Clinical Development at Alnylam Pharmaceuticals

Location: Cambridge, MA United States

Tanya Fischer is a vice president at Alnylam, overseeing the CNS and complement programs. Previously, she served as global project head at Sanofi, where she led the clinical development of the first industry-sponsored clinical trial for a rare genetic form of PD and Gaucher disease. Dr. Fischer is a neurologist with subspecialties in multiple sclerosis and chronic neuropathic pain. As an associate professor at Yale (with an adjunct position in neurology), her research focused on genetic and acquired forms of pain. In 2011, she was awarded the prestigious Presidential Early Career Award for Scientists and Engineers. Dr. Fischer represented Sanofi on the IASB for PPMI and on the GBA-PD committee of the MJFF; she also represented Sanofi at the CPP Consortium. She was the co-chair for AMP-PD since its inception in January 2018-2020 and currently serves on the SAB for the non-profit National Tay-Sachs & Allied Diseases Association.

Associated Grants

  • Targeting Brain-specific Stearoyl-CoA-Desaturase 5 (SCD5) as a Treatment for Parkinson’s Disease


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.